Entering text into the input field will update the search result below

European Ad Comm backs Bristol-Myers' Opdivo for specific use in Hodgkin lymphoma

Oct. 14, 2016 7:17 AM ETBristol-Myers Squibb Company (BMY) StockBy: Douglas W. House, SA News Editor9 Comments
  • The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion recommending approval of Bristol-Myers Squibb's (NYSE:BMY) Opdivo (nivolumab) for the treatment of patients with relapsed/refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin [Seattle Genetics' (SGEN) ADCETRIS].
  • Clinical studies showed Opdivo delivered an objective response rate (ORR) of 66% in these patients.
  • A final decision from the European Commission usually takes ~60 days.

Recommended For You

About BMY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BMY--
Bristol-Myers Squibb Company